Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Denmark

Research and Innovation Action · Running

POINT Preventing non-communicable diseases caused by the post-acute phase of cOvid-19 INfecTion

Coordinator
Kobenhavns Universitet, Denmark
Runs
1 January 2024 to 31 December 2027
Status
Running
EU funding
€6.7m
Total cost
€6.7m
Partners
10 organisations in 8 countries
Type
Research and Innovation Action
Grant agreement
101137196

What the project is doing

In the project's own words, from its summary on CORDIS.

The post-acute phase (PAP) of COVID-19, occurring ≥4 months after the acute phase, is associated with an increased risk for the development of non-communicable diseases (NCDs). The risk of complications in this phase does not depend on the severity of the acute phase. In the EU, more than 183 million cases of COVID-19 have been reported and up to 70% of patients suffer reduced organ function in the PAP. Our conservative estimate it that 5% of people who have suffered COVID-19 are at risk of developing NCDs of the pulmonary, cardiovascular and renal systems due to the PAP.To avoid the significant socioeconomic costs related to this burden, POINT will develop knowledge-based biomarkers for prevention and management of NCDs, a virtual twin model that offers clinical decision support, and clinical guidelines and recommendations for the entire health care value chain with special attention to vulnerable groups.

We will fulfil an unmet need for knowledge and tools to minimize the risk factors of the PAP at the optimal point in time, when healthcare systems will have to redirect their focus from the acute phase of COVID-19 to the post-acute phase. The outcomes of POINT will aid the health care value chain already from an early phase of the project. Furthermore, POINT will correlate and promote knowledge on the development of NCDs in general and the risks of PAP from other infectious diseases.

POINT will meet the challenges with a holistic approach from a truly interdisciplinary consortium consisting of clinical experts, molecular biologists, behavioural scientists, and computer scientists, who will take advantage of cohorts of more than 6 million Europeans, and cross-sectional biobanks from more than 6000 Europeans. Researchers will work together with standardisation experts, an end-user organization representing >120.000 physicians, as well as a dedicated partner for data management ensuring rapid absorption of the outcomes of the project by all stakeholders.

Topics

Who is involved

OrganisationCityCountryRole
Kobenhavns UniversitetKobenhavnDenmarkCoordinator
Katholieke Universiteit LeuvenLeuvenBelgiumParticipant
BioFi AGBaselSwitzerlandAssociatedpartner
Din Deutsches Institut Fuer Normung eVBerlinGermanyParticipant
Det Kgl. BibliotekKobenhavn KDenmarkParticipant
Region HovedstadenHillerodDenmarkParticipant
Tartu UlikoolTartuEstoniaParticipant
Elliniko Instituto Meletis Tis SipsisAthensGreeceParticipant
Fondazione IconsLodiItalyParticipant
Stichting Wonca EuropeLjubljanaSloveniaParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI